These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 22085180)

  • 1. Exenatide BID Observational Study (ExOS): results for primary and secondary endpoints of a prospective research study to evaluate the clinical effectiveness of exenatide BID use in patients with type 2 diabetes in a real-world setting.
    Bergenstal RM; Garrison LP; Miller LA; Hou L; Blickensderfer A; Zagar A; Stanley S; Bhargava A; Wade R; Herman WH
    Curr Med Res Opin; 2011 Dec; 27(12):2335-42. PubMed ID: 22085180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes among patients using exenatide twice daily or insulin in clinical practice in six European countries: the CHOICE prospective observational study.
    Reaney M; Mathieu C; Ostenson CG; Matthaei S; Krarup T; Kiljański J; Salaun-Martin C; Sapin H; Theodorakis M; Guerci B
    Health Qual Life Outcomes; 2013 Dec; 11():217. PubMed ID: 24369764
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Retrospective cohort study evaluating exenatide twice daily and long-acting insulin analogs in a Veterans Health Administration population with type 2 diabetes.
    Bounthavong M; Tran JN; Golshan S; Piland NF; Morello CM; Blickensderfer A; Best JH
    Diabetes Metab; 2014 Sep; 40(4):284-91. PubMed ID: 25059703
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
    Buse JB; Klonoff DC; Nielsen LL; Guan X; Bowlus CL; Holcombe JH; Maggs DG; Wintle ME
    Clin Ther; 2007 Jan; 29(1):139-53. PubMed ID: 17379054
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily.
    Best JH; Boye KS; Rubin RR; Cao D; Kim TH; Peyrot M
    Diabet Med; 2009 Jul; 26(7):722-8. PubMed ID: 19573122
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exenatide twice daily: analysis of effectiveness and safety data stratified by age, sex, race, duration of diabetes, and body mass index.
    Pencek R; Blickensderfer A; Li Y; Brunell SC; Anderson PW
    Postgrad Med; 2012 Jul; 124(4):21-32. PubMed ID: 22913891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes.
    Ratner R; Han J; Nicewarner D; Yushmanova I; Hoogwerf BJ; Shen L
    Cardiovasc Diabetol; 2011 Mar; 10():22. PubMed ID: 21410975
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and tolerability of the new autoinjected suspension of exenatide once weekly versus exenatide twice daily in patients with type 2 diabetes.
    Wysham CH; Rosenstock J; Vetter ML; Dong F; Öhman P; Iqbal N
    Diabetes Obes Metab; 2018 Jan; 20(1):165-172. PubMed ID: 28685973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea.
    Bergenstal R; Lewin A; Bailey T; Chang D; Gylvin T; Roberts V;
    Curr Med Res Opin; 2009 Jan; 25(1):65-75. PubMed ID: 19210140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of twice-daily exenatide in Taiwanese patients with inadequately controlled type 2 diabetes mellitus.
    Lu CH; Wu TJ; Shih KC; Ni E; Reed V; Yu M; Sheu WH; Chuang LM
    J Formos Med Assoc; 2013 Mar; 112(3):144-50. PubMed ID: 23473527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide.
    Pencek R; Brunell SC; Li Y; Hoogwerf BJ; Malone J
    Endocr Pract; 2012; 18(2):227-37. PubMed ID: 22446132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting.
    Yoon NM; Cavaghan MK; Brunelle RL; Roach P
    Clin Ther; 2009 Jul; 31(7):1511-23. PubMed ID: 19695400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes.
    Blevins T; Pullman J; Malloy J; Yan P; Taylor K; Schulteis C; Trautmann M; Porter L
    J Clin Endocrinol Metab; 2011 May; 96(5):1301-10. PubMed ID: 21307137
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of adding exenatide to a regimen of metformin and/or sulfonylurea in type 2 diabetes: an uncontrolled, open-label trial in Hungary.
    Iványi T; Fövényi J; Faludi P; Han J; Macconell L; Wille S; Kiljanski J
    Clin Ther; 2012 Jun; 34(6):1301-13. PubMed ID: 22608106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes of concomitant therapy of exenatide twice daily and basal insulin in patients with type 2 diabetes mellitus: a retrospective database analysis in the United States.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Lee LJ; Fonseca V
    Endocr Pract; 2012; 18(5):700-11. PubMed ID: 22982784
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects of GLP-1 analogues in obese, insulin-using type 2 diabetes in relation to eating behaviour.
    de Boer SA; Lefrandt JD; Petersen JF; Boersma HH; Mulder DJ; Hoogenberg K
    Int J Clin Pharm; 2016 Feb; 38(1):144-51. PubMed ID: 26597956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic outcomes of matched patient populations initiating exenatide BID vs. insulin glargine in an ambulatory care setting.
    Pawaskar M; Li Q; Hoogwerf BJ; Reynolds MW; Faries D; Engelman W; Bruhn D; Bergenstal RM
    Diabetes Obes Metab; 2012 Jul; 14(7):626-33. PubMed ID: 22321776
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide twice daily versus insulin glargine for the treatment of type 2 diabetes in Poland - subgroup data from a randomised multinational trial GWAA.
    Matyjaszek-Matuszek B; Lenart-Lipińska M; Rogalska D; Nowakowski A;
    Endokrynol Pol; 2013; 64(5):375-82. PubMed ID: 24186595
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exenatide therapy in obese patients with type 2 diabetes mellitus treated with insulin.
    Viswanathan P; Chaudhuri A; Bhatia R; Al-Atrash F; Mohanty P; Dandona P
    Endocr Pract; 2007 Sep; 13(5):444-50. PubMed ID: 17872344
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.